Privo Technologies Marks Key Progress in CLN-004 Trial for PRV211 Treatment in Oral Cancer Patients#United_States#Boston#Privo_Technologies#CLN-004#PRV211
Privo Technologies Marks Key Progress in CLN-004 Trial for PRV211 Treatment in Oral Cancer Patients
Privo Technologies successfully completes enrollment for Arm 2 of the CLN-004 trial, achieving primary safety goals without serious adverse events in patients treated with PRV211.
third-news.com
January 23, 2026 at 2:11 PM
Privo Technologies Marks Key Progress in CLN-004 Trial for PRV211 Treatment in Oral Cancer Patients#United_States#Boston#Privo_Technologies#CLN-004#PRV211
Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial#USA#Boston#Privo_Technologies#Oral_Cancer#PRV131
Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial
Privo Technologies has officially begun dosing its first patient in a groundbreaking clinical trial for PRV131, an innovative injectable for oral cavity cancer, showcasing phase 1/2 advancements.
third-news.com
December 10, 2025 at 8:19 PM
Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial#USA#Boston#Privo_Technologies#Oral_Cancer#PRV131
PRV111: A Game-Changer in Non-Surgical Treatment for Oral Cancer#USA#Peabody#Privo_Technologies#PRV111#Oral_Cancer
PRV111: A Game-Changer in Non-Surgical Treatment for Oral Cancer
PRV111 shows promise as a non-surgical therapy for early-stage oral cancer with a remarkable 92% complete response rate in clinical trials. Explore its groundbreaking potential.
third-news.com
November 17, 2025 at 3:51 PM
PRV111: A Game-Changer in Non-Surgical Treatment for Oral Cancer#USA#Peabody#Privo_Technologies#PRV111#Oral_Cancer
Privo Technologies Completes Milestone in Oral Cancer Treatment Trial with PRV111#United_States#Peabody#Privo_Technologies#PRV111#Oral_Cancer
Privo Technologies Completes Milestone in Oral Cancer Treatment Trial with PRV111
Privo Technologies announces the completion of enrollment in the Phase 2 run-in of its PRV111 trial, aimed at reducing surgery for oral cancer patients.
third-news.com
October 14, 2025 at 6:18 PM
Privo Technologies Completes Milestone in Oral Cancer Treatment Trial with PRV111#United_States#Peabody#Privo_Technologies#PRV111#Oral_Cancer
Privo Technologies Broadens CLN-004 Clinical Trial at Major Cancer Centers Across the U.S.#United_States#cancer_therapy#Various#Privo_Technologies#CLN-004
Privo Technologies Broadens CLN-004 Clinical Trial at Major Cancer Centers Across the U.S.
Privo Technologies has launched its CLN-004 clinical trial at top U.S. cancer centers, focusing on innovative therapies for head and neck cancer.
third-news.com
April 28, 2025 at 7:57 PM
Privo Technologies Broadens CLN-004 Clinical Trial at Major Cancer Centers Across the U.S.#United_States#cancer_therapy#Various#Privo_Technologies#CLN-004
BeneVet Oncology Unveiled: A New Era in Companion Animal Healthcare#USA#Peabody#Animal_Health#Privo_Technologies#BeneVet_Oncology
BeneVet Oncology Unveiled: A New Era in Companion Animal Healthcare
Privo Technologies Inc. launches BeneVet Oncology to innovate cancer treatment in pets, leveraging advanced drug delivery platforms. A new commitment to animal health.
third-news.com
March 24, 2025 at 3:09 PM
BeneVet Oncology Unveiled: A New Era in Companion Animal Healthcare#USA#Peabody#Animal_Health#Privo_Technologies#BeneVet_Oncology